Insulin Glulisine Complementing Basal Insulins: A Review of Structure and Activity
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The advancement in protein engineering offers targeted development of insulin analogs that display either faster absorption kinetics or longer time-action profiles compared with human insulin and, therefore, more closely mimic endogenous insulin secretion. Insulin glulisine (3(B)Lys29(B) Glu-human insulin) is a new fast-acting analog that provides absorption and onset of action more rapidly with a shorter duration of action compared with regular human insulin, and thus better resembles physiologic mealtime insulin requirements. Insulin glulisine has been designed to exhibit intrinsic stability while maintaining rapid deployment of insulin monomers. Pharmacokinetic and pharmacodynamic profiling of insulin glulisine in healthy subjects and patients with type 1 and type 2 diabetes not only confirms the rapid absorption and fast action of insulin glulisine compared with human insulin, but also provides evidence that the unique drug formulation may offer additional benefits. Insulin glulisine complements insulin glargine (21(A)-Gly30(Ba)-L-Arg-30(Bb)-L-Arg-human insulin), the first long-acting basal insulin analog that displays a smoothed time-action profile with a 24-h duration of action. Together these analogs offer patients a more physiologic approach to insulin replacement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Glucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria
(2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.397 · Cited by 1,371
β-Cell Glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes.
Robertson, R. P., Harmon, J., Tran, P. O. T., & Poitout, V. (2004) · Diabetes · doi:10.2337/diabetes.53.2007.s119 · Cited by 914
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818 · cited 2×
“Therefore, the glucose infusion rate in patients is zero, 80 if appropriately dosed and insulin demand matches insulin supply for euglycemia, since no compensatory exogenous glucose is needed.”
A desktop guide to Type 2 diabetes mellitus
European Diabetes Policy Group, 1. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00166.x · Cited by 670
Hirsch, I. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040832 · Cited by 667
Management of dyslipidemia in children and adolescents with diabetes
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.7.2194 · Cited by 438
Binder, C., Lauritzen, T., Faber, O., & Pramming, S. (1984) · Diabetes Care · doi:10.2337/diacare.7.2.188 · Cited by 341
Insulin Glulisine Provides Improved Glycemic Control in Patients With Type 2 Diabetes
Dailey, G., Rosenstock, J., Moses, R. G., & Ways, K. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2363 · Cited by 153
Cited by
Correia, M., Neves-Petersen, M. T., Jeppesen, P. B., Gregersen, S., & Petersen, S. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050733 · Cited by 132
“At physiologic pH, monomeric human insulin molecules in solution only exist at very low concentrations (,1610(29) M), while dimers are formed at concentrations of about 1610(26) M [36,39].”
BackgroundInfluentialvan Bon, A. C., Bode, B. W., Sert-Langeron, C., DeVries, J. H., & Charpentier, G. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0224 · Cited by 96
“Therefore the insulin monomers are more stable, and polysorbate 20 prevents fibril formation.(1) Less fibril formation may be important in continuous subcutaneous insulin infusion (CSII) to low the frequency of catheter occlusion.”
Bode, B. W. (2011) · Endocrine Practice · doi:10.4158/ep10260.ra · Cited by 56
Metadata
- Authors
- Becker, R. H. A.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2007-02
- Volume
- 9
- Issue
- 1
- Pages
- 109-121
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W1976763650
- Cited by
- 84
- References
- 10
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin Glulisine Complementing Basal Insulins: A Review of Structure and Activity. https://app.cochat.ai/papers/10.1089/dia.2006.0035
- The paper
- Becker, R. H. A. (2007). Insulin Glulisine Complementing Basal Insulins: A Review of Structure and Activity. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2006.0035
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.